Get the Stockscreener App
0.7998
0.03%
-0.0002
Longeveron Inc stock is traded at $0.7998, with a volume of 546.22K.
It is down -0.03% in the last 24 hours and down -52.11% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$0.80
Open:
$0.7967
24h Volume:
546.22K
Relative Volume:
0.63
Market Cap:
$10.95M
Revenue:
$1.89M
Net Income/Loss:
$-17.92M
P/E Ratio:
-0.1196
EPS:
-6.69
Net Cash Flow:
$-15.62M
1W Performance:
+5.24%
1M Performance:
-52.11%
6M Performance:
-48.73%
1Y Performance:
-69.59%
1-Day Range:
$0.79
$0.82
1-Week Range:
$0.725
$0.8693
52-Week Range:
$0.633
$2.67
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.7998 | 16.82M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference - The Manila Times
Regenerative Medicine Biotech Longeveron to Showcase Clinical Pipeline at Major Investment Conference - Stock Titan
Relative strength of Longeveron Inc. in sector analysisStock Surge & Safe Swing Trade Setup Alerts - Newser
Roth slashes price target on Longeveron - Cantech Letter
LGVN Stock Price, News and Analysis - Cantech Letter
Backtesting results for Longeveron Inc. trading strategiesWall Street Watch & Community Verified Swing Trade Signals - Newser
What does recent volatility data suggest for Longeveron Inc.Earnings Overview Summary & Advanced Technical Signal Analysis - Newser
Longeveron Inc. Faces Regulatory and Manufacturing Challenges Threatening Financial Stability - MSN
Predicting Longeveron Inc. trend using moving averages2025 Volume Leaders & Community Verified Watchlist Alerts - Newser
What’s next for Longeveron Inc. stock pricePortfolio Risk Summary & Breakout Confirmation Alerts - Newser
Longeveron price target lowered to $3 from $10 at Roth Capital - MSN
Detecting price anomalies in Longeveron Inc. with AIShare Buyback & Weekly Watchlist for Consistent Profits - Newser
Short interest data insights for Longeveron Inc.Weekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Technical signs of recovery in Longeveron Inc.July 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - Newser
Longeveron: Buy Rating Backed by Promising Clinical Developments and Stable Financial Outlook - AInvest
Why Longeveron Inc. stock attracts strong analyst attentionRate Hike & High Return Stock Watch Alerts - Newser
Tools to monitor Longeveron Inc. recovery probabilityTrade Risk Assessment & Daily Volume Surge Trade Alerts - Newser
Longeveron Inc. Crosses 200 Day MA — Signal or NoiseQuarterly Profit Review & Stock Portfolio Risk Management - sundaytimes.kr
Longeveron: Buy Rating Backed by Promising Clinical Developments and Strategic Financial Outlook - TipRanks
Longeveron Inc. (NASDAQ:LGVN) Q2 2025 Earnings Call Transcript - Insider Monkey
Is now a turning point for Longeveron Inc.July 2025 Gainers & Weekly Return Optimization Alerts - Newser
What’s the recovery path for long term holders of Longeveron Inc.Portfolio Performance Report & AI Based Trade Execution Alerts - Newser
Longeveron 2025 Q2 Earnings Net Loss Widens Despite EPS Improvement - AInvest
Longeveron Plunges 11.51% on Revenue Drop - AInvest
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Longeveron Posts 32% Revenue Drop in Q2 - AOL.com
Buy Signal for Longeveron Inc. Stock Key Technical Indicators to Watch2025 Price Momentum & Scalable Portfolio Growth Methods - Newser
Automated trading signals detected on Longeveron Inc.July 2025 Analyst Calls & Technical Entry and Exit Alerts - Newser
Longeveron Inc. Reports Q2 2025 Financial Results - TipRanks
Longeveron's Pivotal Clinical Milestones and BLA Pathway: A High-Risk, High-Reward Play in Regenerative Medicine - AInvest
Longeveron: A High-Stakes Bet on Regenerative Medicine's Future - AInvest
Longeveron's Q2 2025 Earnings: Unpacking Key Contradictions in Manufacturing, Regulatory Support, and Clinical Benchmarks - AInvest
Transcript : Longeveron Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Earnings call transcript: Longeveron sees stock surge after Q2 2025 earnings By Investing.com - Investing.com Canada
Longeveron's Stem Cell Therapy for Fatal Child Heart Condition Reaches Critical Trial Phase - Stock Titan
Longeveron Inc (LGVN) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Longeveron's 26% Surge: A Biotech Breakthrough or a Volatility Play? - AInvest
Longeveron's 24.8% Surge: A Biotech Cinderella Story? - AInvest
Does Longeveron Inc. outperform in volatile marketsJuly 2025 Momentum & Low Volatility Stock Recommendations - thegnnews.com
Longeveron shares rise 1.76% premarket after announcing a $17.5 million public offering. - AInvest
What does recent volatility data suggest for Longeveron Inc. [Weekly Trade Report]Free Pattern Based Trade Signal System - Newser
Regression analysis insights on Longeveron Inc. performanceQuarterly Profit Review & Target Return Focused Stock Picks - Newser
Will breakout in Longeveron Inc. lead to full recoveryLong Term Equity Screener with Safety Metrics - Newser
What makes Longeveron Inc. stock price move sharplyIntraday Price Forecast Using Volume Models - Newser
Longeveron Announces Up To $17.5 Million Public Offering - MarketScreener
Longeveron Inc. shares fall 1.01% intraday after closing a $17.5 million public offering. - AInvest
Longeveron Inc (LGVN) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Longeveron (LGVN) to Release Quarterly Earnings on Wednesday - Defense World
What MACD and RSI say about Longeveron Inc.Historical Stock Summary and ROI Review - Newser
Using economic indicators to assess Longeveron Inc. potentialChart Pattern Recognition for Profit Timing - Newser
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longeveron Inc Stock (LGVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):